A Study to Find Out How Multiple Doses of BIIB091 Affect the Electrical Activity of the Heart in Healthy Participants
← catalyst calendarSponsored by Biogen (industry) · BIIB — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
69actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-29 | actual | When the study began enrolling |
| Primary completion | 2025-03-22 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-03-22 | actual | The whole study's end, after follow-up |
| First posted | 2024-08-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-03-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteer
Interventions
- Drug: BIIB091
- Drug: Moxifloxacin
- Drug: BIIB091-matched Placebo
- Drug: Moxifloxacin-matched Placebo
Primary outcomes
what the primary-completion date above is the date OFChange From Baseline in QT Interval Corrected for Heart Rate (QTc) for BIIB091
measured Baseline (Day -1) up to Day 14
Change From Baseline in QT Interval Corrected for Heart Rate (QTc) for Metabolite 23 (M23)
measured Baseline (Day -1) up to Day 14
Permalink · BIIB's whole pipeline · Catalyst calendar · Every registered study · What changed